Acute megakaryoblastic leukemia in Down syndrome
- PMID: 17943965
- DOI: 10.1002/pbc.21353
Acute megakaryoblastic leukemia in Down syndrome
Abstract
Children with Down syndrome (DS) have a 10- to 20-fold increased risk of developing acute leukemia. An estimated 10% of newborns with DS develop Transient Myeloproliferative Disease (TMD) or Transient Leukemia (TL), a clonal accumulation of megakaryoblasts that resolves spontaneously within months. Acute megakaryoblastic leukemia (AMKL) develops in approximately 20% of cases of TMD/TL by 4 years of age. Both the blasts of AMKL and TMD/TL in DS harbor somatic mutations of GATA1, an essential transcriptional regulator of megakaryocytic differentiation. The distinct phenotypes of megakaryoblastic leukemia in DS are a unique biological model of the incremental process of leukemic transformation.
Copyright 2007 Wiley-Liss, Inc.
Similar articles
-
Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.Klin Padiatr. 2005 May-Jun;217(3):126-34. doi: 10.1055/s-2005-836510. Klin Padiatr. 2005. PMID: 15858703
-
Origins of leukaemia in children with Down syndrome.Nat Rev Cancer. 2005 Jan;5(1):11-20. doi: 10.1038/nrc1525. Nat Rev Cancer. 2005. PMID: 15630411 Review.
-
Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.J Pediatr. 2006 May;148(5):687-9. doi: 10.1016/j.jpeds.2005.12.031. J Pediatr. 2006. PMID: 16737888
-
Transient leukemia in newborns with Down syndrome.Pediatr Blood Cancer. 2005 Jan;44(1):29-32. doi: 10.1002/pbc.20141. Pediatr Blood Cancer. 2005. PMID: 15558701 Review.
-
Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.Br J Haematol. 2009 Oct;147(1):3-12. doi: 10.1111/j.1365-2141.2009.07789.x. Epub 2009 Jul 6. Br J Haematol. 2009. PMID: 19594743 Review.
Cited by
-
Malignancy in children with trisomy 21.Oncologist. 2009 Feb;14(2):164-73. doi: 10.1634/theoncologist.2008-0217. Epub 2009 Jan 28. Oncologist. 2009. PMID: 19176633 Free PMC article. Review.
-
Constitutional aneuploidy and cancer predisposition.Hum Mol Genet. 2009 Apr 15;18(R1):R84-93. doi: 10.1093/hmg/ddp084. Hum Mol Genet. 2009. PMID: 19297405 Free PMC article. Review.
-
Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research.Int J Mol Sci. 2023 Mar 11;24(6):5377. doi: 10.3390/ijms24065377. Int J Mol Sci. 2023. PMID: 36982453 Free PMC article. Review.
-
Evolution of myeloid leukemia in children with Down syndrome.Int J Hematol. 2016 Apr;103(4):365-72. doi: 10.1007/s12185-016-1959-5. Epub 2016 Feb 24. Int J Hematol. 2016. PMID: 26910243 Review.
-
CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome.Mol Ther Nucleic Acids. 2017 Jun 16;7:288-298. doi: 10.1016/j.omtn.2017.04.009. Epub 2017 Apr 13. Mol Ther Nucleic Acids. 2017. PMID: 28624204 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
